CellVir develops anti-retrovirals treatments focused on HIV-1 and the viral replication in infected cells.
CellVir, founded in March 2006, is developing a new generation of anti-retrovirals based on a novel therapeutic mode of action. Instead of targeting the inhibition of the catalytic activity of viral enzymes (as do most of today's drugs), CellVir's approach targets host-virus protein-protein interactions which have been shown to be essential for viral replication in infected cells. Drugs operating via this novel mode of action offer two key potential advantages: complementarity to existing drugs because of their lack of susceptibility to cross resistance mechanisms, and a reduced occurrence of viral mutations that lead to drug resistance.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 16, 2008 | Series Unknown | $387K | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Inserm Transfert Initiative | — | Series Unknown |
Genopole | — | Series Unknown |